Anticancer Nanotherapeutics in Clinical Trials: The Work Behind Clinical Translation of Nanomedicine

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Nov 11

PMID 36362156

Authors

Alessandro Parodi

Ekaterina P Kolesova

Maya V Voronina

Anastasia S Frolova

Dmitry Kostyushev

Daria B Trushina

Roman Akasov

Tatiana Pallaeva

Andrey A Zamyatnin Jr

Affiliations

Soon will be listed here.

Abstract

The ultimate goal of nanomedicine has always been the generation of translational technologies that can ameliorate current therapies. Cancer disease represented the primary target of nanotechnology applied to medicine, since its clinical management is characterized by very toxic therapeutics. In this effort, nanomedicine showed the potential to improve the targeting of different drugs by improving their pharmacokinetics properties and to provide the means to generate new concept of treatments based on physical treatments and biologics. In this review, we considered different platforms that reached the clinical trial investigation, providing an objective analysis about their physical and chemical properties and the working mechanism at the basis of their tumoritr opic properties. With this review, we aim to help other scientists in the field in conceiving their delivering platforms for clinical translation by providing solid examples of technologies that eventually were tested and sometimes approved for human therapy.

Citing Articles

Recent advances in self-targeting natural product-based nanomedicines.

Liu H, Jin X, Liu S, Liu X, Pei X, Sun K J Nanobiotechnology. 2025; 23(1):31.

PMID: 39833846 PMC: 11749302. DOI: 10.1186/s12951-025-03092-9.

Nanomedicine: The new trend and future of precision medicine for inflammatory bowel disease.

Li H, Pan M, Li Y, Liang H, Cui M, Zhang M Chin Med J (Engl). 2024; 137(24):3073-3082.

PMID: 39679456 PMC: 11706594. DOI: 10.1097/CM9.0000000000003413.

Mapping the evolution and research landscape of ferroptosis-targeted nanomedicine: insights from a scientometric analysis.

Cao S, Wei Y, Yue Y, Wang D, Yang J, Xiong A Front Pharmacol. 2024; 15:1477938.

PMID: 39386034 PMC: 11461269. DOI: 10.3389/fphar.2024.1477938.

Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials.

Serras A, Faustino C, Pinheiro L Pharmaceutics. 2024; 16(8).

PMID: 39204392 PMC: 11359152. DOI: 10.3390/pharmaceutics16081047.

Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer.

Oehler J, Rajapaksha W, Albrecht H J Pers Med. 2024; 14(7).

PMID: 39063977 PMC: 11278299. DOI: 10.3390/jpm14070723.

References

Fassas A, Anagnostopoulos A . The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma. 2005; 46(6):795-802. DOI: 10.1080/10428190500052438. View

Verco J, Johnston W, Baltezor M, Kuehl P, Gigliotti A, Belinsky S . Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac) in a Rodent Model. J Aerosol Med Pulm Drug Deliv. 2018; 32(2):99-109. PMC: 6477588. DOI: 10.1089/jamp.2018.1467. View

Hoffmann C, Calugaru V, Borcoman E, Moreno V, Calvo E, Liem X . Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx. Eur J Cancer. 2021; 146:135-144. DOI: 10.1016/j.ejca.2021.01.007. View

Kemp J, Kwon Y . Cancer nanotechnology: current status and perspectives. Nano Converg. 2021; 8(1):34. PMC: 8560887. DOI: 10.1186/s40580-021-00282-7. View

Hersh E, Del Vecchio M, Brown M, Kefford R, Loquai C, Testori A . A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. Ann Oncol. 2015; 26(11):2267-74. PMC: 6279094. DOI: 10.1093/annonc/mdv324. View

Lux F, Detappe A, Dufort S, Sancey L, Louis C, Carme S . [Ultrasmall nanoparticles for radiotherapy: AGuIX]. Cancer Radiother. 2015; 19(6-7):508-14. DOI: 10.1016/j.canrad.2015.05.019. View

Hama M, Ishima Y, Chuang V, Ando H, Shimizu T, Ishida T . Evidence for Delivery of Abraxane via a Denatured-Albumin Transport System. ACS Appl Mater Interfaces. 2021; 13(17):19736-19744. DOI: 10.1021/acsami.1c03065. View

Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N . CPX-351 (vyxeos) in AML. Leuk Lymphoma. 2019; 61(2):288-297. DOI: 10.1080/10428194.2019.1660970. View

Monk B, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita A . Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Ann Oncol. 2015; 26(5):914-920. DOI: 10.1093/annonc/mdv071. View

10.

Voss M, Hussain A, Vogelzang N, Lee J, Keam B, Rha S . A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. Ann Oncol. 2017; 28(11):2754-2760. DOI: 10.1093/annonc/mdx493. View

11.

Ghosh B, Biswas S . Polymeric micelles in cancer therapy: State of the art. J Control Release. 2021; 332:127-147. DOI: 10.1016/j.jconrel.2021.02.016. View

12.

Tian X, Nguyen M, Foote H, Caster J, Roche K, Peters C . CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α. Cancer Res. 2016; 77(1):112-122. PMC: 5214961. DOI: 10.1158/0008-5472.CAN-15-2951. View

13.

Escudier B, Dorval T, Chaput N, Andre F, Caby M, Novault S . Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med. 2005; 3(1):10. PMC: 554765. DOI: 10.1186/1479-5876-3-10. View

14.

Sohal D, Duong M, Ahmad S, Gandhi N, Beg M, Wang-Gillam A . Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021; 7(3):421-427. PMC: 7821078. DOI: 10.1001/jamaoncol.2020.7328. View

15.

Anas Tomeh M, Hadianamrei R, Zhao X . A Review of Curcumin and Its Derivatives as Anticancer Agents. Int J Mol Sci. 2019; 20(5). PMC: 6429287. DOI: 10.3390/ijms20051033. View

16.

Davis M . The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm. 2009; 6(3):659-68. DOI: 10.1021/mp900015y. View

17.

Morse M, Garst J, Osada T, Khan S, Hobeika A, Clay T . A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005; 3(1):9. PMC: 551593. DOI: 10.1186/1479-5876-3-9. View

18.

Dulinska-Litewka J, Lazarczyk A, Halubiec P, Szafranski O, Karnas K, Karewicz A . Superparamagnetic Iron Oxide Nanoparticles-Current and Prospective Medical Applications. Materials (Basel). 2019; 12(4). PMC: 6416629. DOI: 10.3390/ma12040617. View

19.

Allen T, Martin F . Advantages of liposomal delivery systems for anthracyclines. Semin Oncol. 2005; 31(6 Suppl 13):5-15. DOI: 10.1053/j.seminoncol.2004.08.001. View

20.

Volovat S, Ciuleanu T, Koralewski P, Grilley Olson J, Croitoru A, Koynov K . A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer. Oncotarget. 2020; 11(33):3105-3117. PMC: 7443368. DOI: 10.18632/oncotarget.27684. View